Skip to content
All posts

Journey Biosciences launches NaviDKD® to predict diabetes-related kidney complications

First and only scientifically-based screening technology provides an early read on the risk of developing kidney disease for people with diabetes, giving them and their doctors time to take preventive action and improve outcomes.

Journey Biosciences, Inc., a biotechnology company offering biomarker-based predictive risk screening technologies, today announced the launch of its flagship product—NaviDKD.

NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass™ reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.

"For the one-in-three people with diabetes who will develop kidney disease, NaviDKD provides an opportunity to change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "By identifying those at elevated or high risk of developing DKD before any clinical signs or symptoms, the conversation between doctors and patients can focus on taking proactive, preventive actions instead of reacting to an unwanted diagnosis."

All NaviDKD blood samples are processed in Journey Biosciences' laboratory in Cleveland, Ohio, which received CLIA certification in August 2022. 

About Journey Biosciences

Journey Biosciences is shifting the future of care through predictive innovations. Our flagship solution blends the precision of NaviDKD®, a clinically-validated predictive screening, with the AI-driven insights of Compass, offering up to 12 years of advanced diabetes-related kidney disease (DKD) detection and tailored intervention strategies. This groundbreaking approach improves patient outcomes, optimizes resource allocation, and reduces costs. Discover more about our transformative approach at

For media inquiries: